TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

1.1 OVERVIEW

1.1.1 MARKET SYNOPSIS

2 MARKET INTRODUCTION

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 RESEARCH OBJECTIVE

2.4 LIST OF ASSUMPTIONS

3 RESEARCH METHODOLOGY

3.1 OVERVIEW

3.2 DATA MINING

3.3 SECONDARY RESEARCH

3.4 PRIMARY RESEARCH

3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS

3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS

3.5 FORECASTING TECHNIQUES

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION

3.6.1 BOTTOM-UP APPROACH

3.6.2 TOP-DOWN APPROACH

3.7 DATA TRIANGULATION

3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW

4.2 DRIVERS

4.2.1 GROWING IMPORTANCE OF THE AESTHETIC APPEAL AND AWARENESS

4.2.2 INCREASING PREVALENCE OF VITLIGO

4.3 RESTRAINTS

4.3.1 LACK OF TRAINED PROFESSIONALS

4.4 OPPORTUNITIES

4.4.1 RISING NUMBER OF CLINICAL TRIALS

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS

5.1.1 R&D

5.1.2 MANUFACTURING

5.1.3 DISTRIBUTION & SALES

5.1.4 POST-SALES MONITORING

5.2 PORTER’S FIVE FORCES MODEL

5.2.1 THREAT OF NEW ENTRANTS

5.2.2 BARGAINING POWER OF SUPPLIERS

5.2.3 THREAT OF SUBSTITUTES

5.2.4 BARGAINING POWER OF BUYERS

5.2.5 INTENSITY OF RIVALRY

5.3 IMPACT OF COVID-19 ON THE VITILIGO TREATMENT MARKET

5.3.1 IMPACT ON SUPPLY CHAIN

5.3.2 IMPACT ON REGION

5.3.3 IMPACT ON DEMAND AND SUPPLY

6 GLOBAL VITILIGO TREATMENT MARKET, BY TYPE

6.1 OVERVIEW

6.2 SEGMENTAL VITILIGO

6.3 NON-SEGMENTAL VITILIGO

7 GLOBAL VITILIGO TREATMENT MARKET, BY TREATMENT TYPE

7.1 OVERVIEW

7.2 THERAPY

7.2.1 DEPIGMENTATION

7.2.2 LIGHT

7.3 SURGERY

7.3.1 SKIN GRAFTING

7.3.2 BLISTER GRAFTING

7.3.3 MICRO-PIGMENTATION

7.4 MEDICATION

7.4.1 TOPICAL CORTICOSTEROIDS

7.4.2 IMMUNOSUPPRESSIVE

8 GLOBAL VITILIGO TREATMENT MARKET, BY END USER

8.1 OVERVIEW

8.2 HOSPITALS

8.3 AMBULATORY CLINICS

8.4 OTHERS

9 GLOBAL VITILIGO TREATMENT MARKET, BY REGION

9.1 OVERVIEW

9.2 NORTH AMERICA

9.2.1 US

9.2.2 CANADA

9.3 EUROPE

9.3.1 GERMANY

9.3.2 FRANCE

9.3.3 UK

9.3.4 ITALY

9.3.5 SPAIN

9.3.6 REST OF EUROPE

9.4 ASIA-PACIFIC

9.4.1 CHINA

9.4.2 JAPAN

9.4.3 INDIA

9.4.4 SOUTH KOREA

9.4.5 AUSTRALIA

9.4.6 REST OF ASIA-PACIFIC

9.5 REST OF THE WORLD

9.5.1 MIDDLE EAST

9.5.2 AFRICA

9.5.3 LATIN AMERICA

10 COMPETITIVE LANDSCAPE

10.1 OVERVIEW

10.2 COMPETITIVE BENCHMARKING

10.3 MAJOR GROWTH STRATEGY IN VITILIGO TREATMENT MARKET

10.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN VITILIGO TREATMENT MARKET

10.5 KEY DEVELOPMENT ANALYSIS

10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES

10.6.1 PRODUCT APPROVALS/PRODUCT LAUNCHES/DRUG PIPELINE

10.6.2 MERGERS & ACQUISITIONS

10.7 MAJOR PLAYERS SALES ANALYSIS

10.7.1 SALES & OPERATING INCOME, 2021

10.7.2 MAJOR PLAYERS R&D ANALYSIS, 2021

11 COMPANY PROFILE

11.1 INCYTE

11.1.1 COMPANY OVERVIEW

11.1.2 FINANCIAL OVERVIEW

11.1.3 PRODUCTS OFFERED

11.1.4 KEY DEVELOPMENTS

11.1.5 SWOT ANALYSIS

11.1.6 KEY STRATEGIES

11.2 BAUSCH HEALTH COMPANIES INC.

11.2.1 COMPANY OVERVIEW

11.2.2 FINANCIAL OVERVIEW

11.2.3 PRODUCTS OFFERED

11.2.4 KEY DEVELOPMENTS

11.2.5 SWOT ANALYSIS

11.2.6 KEY STRATEGIES

11.3 KONINKLIJKE PHILIPS N.V.

11.3.1 COMPANY OVERVIEW

11.3.2 FINANCIAL OVERVIEW

11.3.3 PRODUCTS OFFERED

11.3.4 KEY DEVELOPMENTS

11.3.5 SWOT ANALYSIS

11.3.6 KEY STRATEGIES

11.4 DR. REDDY’S LABORATORIES LTD.

11.4.1 COMPANY OVERVIEW

11.4.2 FINANCIAL OVERVIEW

11.4.3 PRODUCTS OFFERED

11.4.4 KEY DEVELOPMENTS

11.4.5 SWOT ANALYSIS

11.4.6 KEY STRATEGIES

11.5 STRATA SKIN SCIENCES

11.5.1 COMPANY OVERVIEW

11.5.2 FINANCIAL OVERVIEW

11.5.3 PRODUCTS OFFERED

11.5.4 KEY DEVELOPMENTS

11.5.5 KEY STRATEGIES

11.6 CLINUVEL PHARMACEUTICALS LTD

11.6.1 COMPANY OVERVIEW

11.6.2 FINANCIAL OVERVIEW

11.6.3 PRODUCTS OFFERED

11.6.4 KEY DEVELOPMENTS

11.6.5 SWOT ANALYSIS

11.6.6 KEY STRATEGIES

11.7 ISSAR PHARMACEUTICALS PVT. LTD.

11.7.1 COMPANY OVERVIEW

11.7.2 FINANCIAL ANALYSIS

11.7.3 PRODUCTS OFFERED

11.7.4 KEY DEVELOPMENTS

11.7.5 KEY STRATEGIES

11.8 KERNEL MEDICAL EQUIPMENT CO., LTD.

11.8.1 COMPANY OVERVIEWS

11.8.2 FINANCIAL OVERVIEW

11.8.3 PRODUCTS OFFERED

11.8.4 KEY DEVELOPMENTS

11.8.5 KEY STRATEGIES

11.9 LIGHTSOURCES

11.9.1 COMPANY OVERVIEW

11.9.2 FINANCIAL ANALYSIS

11.9.3 PRODUCTS OFFERED

11.9.4 KEY DEVELOPMENTS

11.9.5 KEY STRATEGIES

11.10 ROIVANT SCIENCES LTD.

11.10.1 COMPANY OVERVIEW

11.10.2 FINANCIAL ANALYSIS

11.10.3 PRODUCTS OFFERED

11.10.4 KEY DEVELOPMENTS

11.10.5 PRODUCTS OFFERED

11.10.6 KEY STRATEGIES

12 APPENDIX

12.1 REFERENCES

12.2 RELATED REPORTS